Vaccination against the HER-2/neu oncogenic protein.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Phenotypic Analysis of Antigen-Specific T Lymphocytes

1996 • 3,611 citations

NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

2000 • 2,394 citations

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1998 • 2,373 citations

Humanization of an anti-p185HER2 antibody for human cancer therapy.

1992 • 1,867 citations

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

1992 • 1,200 citations

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.

1996 • 1,129 citations

Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients

1998 • 1,103 citations

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

1999 • 983 citations

Dominance and Crypticity of T Cell Antigenic Determinants

1993 • 838 citations

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

2000 • 544 citations

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

1995 • 542 citations

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

1995 • 446 citations

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

2001 • 436 citations

Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines

2002 • 426 citations

Histological and biological evolution of human premalignant breast disease.

2001 • 424 citations

Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers

1999 • 423 citations

IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice

2000 • 419 citations

Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.

2000 • 418 citations

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer

1992 • 415 citations

Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells

2001 • 407 citations

In vivo generation of human dendritic cell subsets by Flt3 ligand

2000 • 397 citations

Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients

1998 • 359 citations

Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma

2001 • 359 citations

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

1997 • 347 citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1996 • 308 citations

The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors

1998 • 235 citations

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

2002 • 233 citations

Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.

1998 • 227 citations

Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

1998 • 220 citations

Induction of anti-self-immunity to cure cancer

1995 • 207 citations

First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer

2001 • 194 citations

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1996 • 185 citations

Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas

1999 • 176 citations

HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.

1994 • 174 citations

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

2000 • 161 citations

In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.

1994 • 150 citations

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

1995 • 149 citations

Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity

2001 • 136 citations

Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.

2001 • 134 citations

Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.

1984 • 133 citations

HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer

2000 • 127 citations

Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene

1993 • 124 citations

Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.

1995 • 122 citations

Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.

2002 • 119 citations

Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.

2000 • 116 citations

Prevention of Peripheral Tolerance by a Dendritic Cell Growth Factor: Flt3 Ligand as an Adjuvant

1998 • 110 citations

Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.

1995 • 110 citations

Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.

1994 • 94 citations

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes

1998 • 94 citations

Ligand and p185c-neu density govern receptorinteractions and tyrosine kinase activation.

1994 • 92 citations

Therapy with cultured T cells: principles revisited

1997 • 90 citations

Manipulation of Avidity to Improve Effectiveness of Adoptively Transferred CD8+ T Cells for Melanoma Immunotherapy in Human MHC Class I-Transgenic Mice

2001 • 86 citations

MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope

1999 • 86 citations

HER-2/neu Oncogenic Protein: Issues in Vaccine Development

1998 • 80 citations

Driver Clones and Determinant Spreading

2000 • 79 citations

Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design

2001 • 77 citations

ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ANTIGENS CAN BE DETECTED IN THE SERUM OF PATIENTS WITH PROSTATE CANCER

2000 • 76 citations

Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer

1999 • 68 citations

Nitric Oxide Inhibits the Proliferation of T-Helper 1 and 2 Lymphocytes without Reduction in Cytokine Secretion

1999 • 66 citations

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope

2001 • 65 citations

γδ cells regulate autoimmunity

1997 • 61 citations

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

2000 • 57 citations

Accumulation of γ/δ T Cells in Human Dysgerminoma and Seminoma: Roles in Autologous Tumor Killing and Granuloma Formation

1995 • 55 citations

Induction of Dendritic Cells (DC) by Flt3 Ligand (FL) Promotes the Generation of Tumor-Specific Immune Responses In Vivo

1998 • 52 citations

TCR γδ Bearing T Lymphocytes Infiltrating Human Primary Cutaneous Melanomas

1992 • 49 citations

The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells

2001 • 48 citations

Dominance and Crypticity of T Cell Antigenic Determinants

1993 • 45 citations

In vivo generation of human dendritic cell subsets by Flt3 ligand

2000 • 44 citations

Changes in an HER-2 Peptide Upregulating HLA-A2 Expression Affect Both Conformational Epitopes and CTL Recognition

1995 • 36 citations

Expansion of HER2/neu-Specific T Cells Ex Vivo Following Immunization with a HER2/neu Peptide-Based Vaccine

2001 • 32 citations

The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells

2000 • 32 citations

Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells

2000 • 31 citations

Localization of T cell receptor (TCR)- γδ+ T cells into human colorectal cancer: flow cytometric analysis of TCR-γδ expression in tumour-infiltrating lymphocytes

1995 • 29 citations

CD4+, HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells

2000 • 26 citations

CD4+, HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells

2000 • 15 citations

Expansion and Immunological Study of Human Tumor Infiltrating Gamma/Delta T Lymphocytes in vitro<sup>1</sup>

1999 • 14 citations

Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.

1999 • 13 citations

ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ANTIGENS CAN BE DETECTED IN THE SERUM OF PATIENTS WITH PROSTATE CANCER

2000 • 6 citations

Identification of HER2/neu‐derived peptide epitopes recognized by gastric cancer‐specific cytotoxic T lymphocytes

1998 • 4 citations

MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope

1999 • 1 citations

Accumulation of gamma/delta T cells in human dysgerminoma and seminoma : roles in autologous tumor killing and granuloma formation

1999 • 1 citations